A quiet revolution in global public health: The world health organization's prequalification of medicines programme

Journal of Public Health Policy

Volumn 35, Issue 2, 2014, Pages 137-161

  'T Hoen, Ellen F M ^a   Hogerzeil, Hans V ^b   Quick, Jonathan D ^c   Sillo, Hiiti B ^d  

^a Independent Consultant   (France)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

^c MANAGEMENT SCIENCES FOR HEALTH   (United States)

^d Tanzania Food and Drugs Authority   (Tanzania)

Author keywords

access to medicines; HIV; Medicines quality; patents; WHO Prequalification of medicines programme

Indexed keywords

DRUGS, GENERIC;

COST-BENEFIT ANALYSIS; DEVELOPING COUNTRIES; DRUG APPROVAL; DRUG COSTS; ECONOMICS; GLOBAL HEALTH; HEALTH SERVICES ACCESSIBILITY; HUMANS; PROGRAM DEVELOPMENT; PUBLIC HEALTH; STANDARDS; TRENDS; WORLD HEALTH ORGANIZATION;

COST-BENEFIT ANALYSIS; DEVELOPING COUNTRIES; DRUG APPROVAL; DRUG COSTS; DRUGS, GENERIC; GLOBAL HEALTH; HEALTH SERVICES ACCESSIBILITY; HUMANS; PROGRAM DEVELOPMENT; PUBLIC HEALTH; WORLD HEALTH ORGANIZATION;

EID: 84899089057     PISSN: 01975897     EISSN: 1745655X     Source Type: Journal    
DOI: 10.1057/jphp.2013.53     Document Type: Review

References (43)

1. World Health Organization (WHO). (1987) The Rational Use of Drugs: Report of the Conference of Experts Nairobi, 26-29 November, 1985.
2. World Health Organization (WHO). (2011) Survey of the quality of anti-tuberculosis medicines circulating in selected newly independent states of the former Soviet Union. http://apps.who.int/medicinedocs/documents/s19053en/ s19053en.pdf, accessed 18 November 2013.
3. World Health Organization (WHO). (2013) WHO List of Prequalified Medicinal Products. http://apps.who.int/prequal/query/ProductRegistry.aspx, accessed 18 November 2013.
4. UNAIDS. (2012) World AIDS Day Report 2012. Geneva.
5. Gellman, B. (2000) An unequal calculus of life and death; as millions perished in pandemic, firms debated access to drugs; players in the debate over drug availability and pricing. The Washington Post. 27 December, p. A01.
6. t Hoen, E., Berger, J., Calmy, A. and Moon, S. (2011) Driving a decade of change: HIV/AIDS, patents and access to medicines for all. Journal of the International AIDS Society. 14:2-12.
7. World Trade Organization (WTO). (2007) The results of the Uruguay round of multilateral trade negotiations. Geneva, http://www.wto.org/english/docs-e/ legal-e/legal-e.htm, accessed 18 November 2013.
8. McNeil Jr, D. (2002) New List of Safe AIDS Drugs. The New York Times. 20 March, http://www.nytimes.com/2002/03/21/world/new-list-of-safe-aids-drugs- despite-industry-lobby.html, accessed 18 November 2013.
9. Connor, J., Rafter, N. and Rodgers, A. (2004) Do Fixed-Dose Combination Pills Or Unitof-use Packaging Improve Adherence A Systematic Review. Bulletin of the World Health Organization. 82:935-9, http://apps.who.int/iris/handle/10665/ 72678, accessed 18 November 2013.
10. Laurent, C. et al ANRS 1274 study group (2004) Effectiveness and safety of a generic fixeddose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: Open-label multicentre trial. The Lancet 364(9428): 29-34.
11. GlaxoSmithKline (GSK) offered a combination of abacavir, lamivudine and zidovudine in one pill in early 2000.
12. Bate, R. (2005) Slippery AIDS Statistics. American Enterprise Institute. AEI Online, http://67.208.89.102/article/health/slippery-aids-statistics/, accessed 18 November 2013.
13. Adelman, C. and Norris, J. (2004) Fighting AIDS on the Cheap. Hudson Institute, https://www .hudson.org/index.cfmfuseaction=publication- details&id=3252, accessed 18 November 2013.
14. (2004) Generics for AIDS (Editorial). Nature Immunology 5:1089.
15. Brown, D. (2004) Bush?s AIDS Program Balks at Foreign Generics US Insistence on More Tests Complicates Rollout. The Washington Post, 27 March, p. A03.
16. Dyer, O (2004) Bush accused of blocking access to cheap AIDS drugs. British Medical Journal 328:783.1.
17. Act Up. (2004) Global AUDS Coordinator Tobias Defends US Policy Not to Use Generic Fixed-Dose Combination Antoretroviral Drugs, 29 April, http://www.actupny.org/reports/genericszap. html, accessed 18 November 2013.
18. ?t Hoen, E. (2004) Generic drugs for fighting AIDS. The New York Times Opinion, 2 April, http://www.nytimes.com/2004/04/02/opinion/02iht-edlet-ed3-4. html, accessed 18 November 2013.
19. R?go, L. (2004) HowWHO ensures the quality of antiretrovirals and other essential medicines, 7 September, http://www.who.int/hiv/amds/capacity/ken-rago. pdf, accessed 18 November 2013.
20. World Health Organization (WHO). (2004) Scientific and technical principles for fixed dose combination products. Botswana: WHO, 22 April.
21. organisations. (2004) Letter to Ambassador Randall Tobias. Re: Generic medicines and US-initiatied conference on Fixed-Dose Combinations, 29 March, http://www.cptech.org/ip/health/aids/fdc/signon03292004.html, accessed 18 November 2013.
22. Brown, S. and Lee, B. (2004) Letter to Ambassador Randall Tobias, 24 March, http://www .cptech.org/ip/health/aids/fdc/brown03242004.pdf, accessed 18 November 2013.
23. United States General Accounting Office. (2004) Report to the Chairman, Subcommittee on Foreign Operations, Export Financing, and Related Programs, Committee on Appropriations, House of Representatives. GLOBAL HEALTH, USAIDS Coordinator Addressing Some Key Challenges to Expanding Treatment, but Others Remain. GOA-04-784, http://www.gao.gov/assets/250/243344.pdf, accessed 18 November 2013.
24. Kapstein, E.B. and Busby, J.W. (2013) AIDS Drugs for All: Social Movements and Market Transformation. Cambridge, UK: Cambridge University Press, p. 207.
25. World Health Assembly Resolution: WHA/50 2004.
26. M?decins Sans Fronti?res (MSF). (2004) Briefing note: Two Cipla AIDS Drugs Removed from WHO Prequalification List, 16 June, http://www.msfaccess.org/ sites/default/files/MSF- assets/HIV-AIDS/Docs/AIDS-briefing-CiplaAIDSDrugWHOPQ- ENG-2004.pdf, accessed 18 November 2013.
27. (2004) The important world of drug prequalification. The Lancet 364(9448):1830.
28. Van Zyl, A.J. (2011) Ensuring the quality of medicines-A decade of prequalification. WHO Drug Information 25: 231-239.
29. World Health Organization (WHO). (2013) Prequalification of active pharmaceutical ingredients. WHO Drug Information 26(3): 255-260.
30. World Health Organization (WHO). (2011) The WHO prequalification programme and the Medicines Patent Pool: A Primer, http://www. medicinespatentpool.org/the-worldhealth-organization-prequalification-of- medicines-programme-and-the-patent-pool/, accessed 18 November 2013.
31. World Health Organization (WHO). (2009) WHO medicines prequalification: Progress in 2008. WHO Drug Information 23(1): 3-7.
32. World Health Organization (WHO). (2011) Who prequalification of medicines programme (Pqp) facts and figures for 2011, http://apps.who.int/prequal/info- general/documents/annual- reports/2011-PQP-Summary.pdf, accessed 18 November 2013.
33. World Health Organization (WHO). (2013) WHO model Lists of Essential Medicines, http://www.who.int/medicines/publications/essentialmedicines/en/, accessed 18 November 2013.
34. Kaplan, W. and Laing, R. (2004) Priority Medicines for Europe and the World. World Health Organization Department of Essential Drugs and Medicines Policy, http://whqlibdoc.who.int/hq/2004/WHO-EDM-PAR-2004.7.pdf, accessed 18 November 2013.
35. Kaplan, W., Wirtz, V.J., Mantel-Teeuwisse, A., Stolk, P., Duthey, B. and Laing, R. (2013) Priority Medicines for Europe and the World-2013 Update. World Health Organization, http://www.who.int/medicines/areas/priority-medicines/en/, accessed 18 November 2013.
36. WHO/HTP/PSM/QSM (2005). A Business Plan for the Prequalification Program 2006-2007. 1 September.
37. USAID, SCMC, PEPFAR. (2012) Six years of saving lives through stronger public health supply chains, http://scms.pfscm.org/scms/docs/scms-6year-final. pdf, accessed 18 November 2013.
38. UNITAID. (2013) UNITAID Strategy 2013-2016, http://www.unitaid.eu/images/ strategy/UNITAID-Strategy-2013-2016-Full-English.pdf, accessed 18 November 2013.
39. World Health Organization (WHO). (2013) 15 facts on HOV treatment scale-up and new WHO ARV guidelines 2013, http://www.who.int/hiv/pub/guidelines/ arv2013/15facts/en/index .html, accessed 15 November 2013.
40. World Health Organization (WHO). (2010) Assessment of Medicines Regulatory Systems in Sub-Saharan African Countries. Geneva, http://www.who.int/healthsystems/Assessment26 African-countries.pdf, accessed 18 November 2013.
41. United States Government Accountability Office. (2013) President?s Emergency Plan for AIDS relief. Drug Supply Chains Are Stronger, but More Steps are Needed to Reduce Risks. GAO-13-483, http://www.gao.gov/assets/660/654247. pdf, accessed 18 November 2013.
42. US Food and Drug Administration (USFDA). (2004) Approved and Tentatively Approved Antiretrovirals in Association with the President?s Emergency Plan, http://www.fda.gov/InternationalPrograms/FDABeyondOurBordersForeignOffices/ AsiaandAfrica/ucm119231.htm, accessed 18 November 2013.
43. Waning, B. et al (2010) Intervening in global markets to improve access to HIV/AIDS treatment: An analysis of international policies and the dynamics of global antiretroviral medicines markets. Globalization and Health 14(1):9.